HARTE HANKS INC Form 8-K August 14, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 14, 2017 (August 9, 2017)

Date of Report (Date of Earliest Event Reported)

Harte Hanks, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 1-7120 (Commission File Number) **74-1677284** (I.R.S. Employer Identification No.)

9601 McAllister Freeway, Suite 610

San Antonio, Texas 78216

(210) 829-9000

(Address of principal executive offices and Registrant s telephone number, including area code)

neck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o 240.14d	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR -2(b))
o 240.13e	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR -4(c))
	y check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of the Property of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging	growth company O
	ging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. O

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 9, 2017, Harte Hanks, Inc. (the Company) received a notice from the New York Stock Exchange (the NYSE) indicating that the average closing price of the Company s common stock had fallen below \$1.00 per share over a period of 30 consecutive trading days, which is the minimum average share price for continued listing on the NYSE under Rule 802.01C of the NYSE Listed Company Manual. As of August 7, 2017, the 30 trading-day average closing price of the Company s common stock was \$0.99 per share.

As required by the NYSE, the Company will notify the NYSE within 10 business days of receipt of the August 9, 2017 letter that it intends to cure the deficiency and to return to compliance with the NYSE continued listing requirement. Under NYSE rules, the Company has six months following receipt of the notification to regain compliance with the minimum share price requirement. The Company can regain compliance at any time during the six-month cure period if the Company s common stock has a closing share price of at least \$1.00 on the last trading day of any calendar month during the period and also has an average closing share price of at least \$1.00 over the 30-trading day period ending on the last trading day of that month or on the last day of the cure period.

The notice has no immediate impact on the listing of the Company s common stock, which will continue to trade on the NYSE under the symbol HHS. The Company intends to actively monitor the closing share price for its common stock and will consider available options, including equity-based actions, such as a reverse stock split, to resolve the deficiency and regain compliance with Rule 802.01C of the NYSE Listed Company Manual.

The NYSE informed the Company in its notice that the Company is required to issue a press release announcing that it had received the notice of noncompliance. The Company issued such a press release on August 14, 2017 (a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K).

Item 9.01	Financial Statements	and Exhibits.	
(d) Exhibits. The following	exhibits are being filed or furnish	ed herewith:	
Exhibit Number		Exhibit T	litle
99.1 A	August 14, 2017 Press Release of Harte Hanks, Inc.		
		SIGNATURE	
Pursuant to the requirement undersigned hereunto duly		of 1934, the registrant has c	luly caused this report to be signed on its behalf by the
		arte Hanks, Inc. ated: August 14, 2017	
	Ву		/s/Robert L. R. Munden Executive Vice President, General Counsel & Secretary
		3	

EXHIBIT INDEX

Exhibit Number	Exhibit Title	
99.1	August 14, 2017 Press Release of Harte Hanks, Inc.	

4